Open Access Subscription Access
Open Access Subscription Access
Formulation and Characterization of Tramadol HCl Transdermal Patch
Transdermal drug delivery leads direct access to the systemic circulation through the skin which bypasses drugs from the hepatic first pass metabolism leading to increase bioavailability. Tramadol HCl has been selected as model drug because it has low bioavailability. It exhibit all physicochemical characteristics required for the transdermal patch. Transdermal patches of Tramadol HCl were prepared by solvent casting method using different polymers i.e. HPMCK4M, HPMCK15M, HPMCE5.Propyleneglycol was used as plasticizer and methanol was used to dissolve the drug. Water was used as solvent to dissolve the polymer. The prepared formulations were evaluated for drug content uniformity, in vitro diffusion study, thickness, tensile strength, moisture content, folding endurances etc. Amongst all formulation, formulation F3 had more desirable characteristic and shows 88.36% drug release in 12hr. Release kinetic can be described by Higuchi model with anomalous diffusion as a release mechanism. The Transdermal patch formulated from HPMCK4M, HPMCK15M and HPMCE5 showed satisfactory physicochemical properties. The ratios of hydrophilic polymers HPMCK4M, HPMCK15M and HPMCE5 good moisture content property, good tensile strength, folding endurances and in-vitro drug release. So, it can be concluded that such a matrix type patches of HPMCK4M, HPMC K15M and HPMCE5 could be a good carrier in transdermal delivery of Tramadol HCl. FTIR studies showed there were no incompatibilities between drug and other excipients
Transdermal Patch, Tramadol HCl, HPMC.
- Kandavilli S, Nair V, Panchagnula R. Polymers in transdermal drug delivery systems, Pharmaceutical Technology 2002, 62-78. Available from: http://www.pharmtech.com/.
- Guy RH. Current status and future prospects of transdermal drug delivery, Pharm Res 1996, 13, 1765-1769.
- Guy RH, Hadgraft J, Bucks DA. Transdermal drug delivery and cutaneous metabolism, Xenobiotica 1987, 7, 325-343.
- Chein YW. Transdermal Controlled Systemic Medication. New York and Basel, Marcel Dekker Inc. 1987; 159-176.
- Comfort AR, Sherchuk I, Ohe JH, Dinh SM. in-vitro characterization of a solvent controlled nitroglycerine transdermal system. J Controlled Rel 1995; 34, 193-201.
- Carpel MC, Erasmo AME, Rawena SW, Elizebath PH, Rondoll Z. Drug Intelligence Clinical Pharmacy; 1987.
- Chien Yie W. Transdermal drug delivery and delivery systems. 2nd Ed. New York: Marcel Dekkar Inc; 1992.
- Obsorne, Hattzenbuler. The influence of skin surface lipids on topical formulations. New York: Marcel Dekker Inc; 1990.
- Marjukka ST, Bouwsira JA, Urtti A. Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations. J Control Rel 1999; 59:149-61.
- Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 2004; 3(2):115-24.
- Chatterjee CC. Human physiology. Medical allied agency. Vol II. Calcutta India: p1:p68-80.
- Guy RH. Current status and future prospects of transdermal drug delivery. Pharm Res 1996;13(12):1765-69.
- Hadgraft J. Recent developments in topical and transdermal delivery. Eur J Drug Metab Pharmacokinetic 1996; 21:165-73.
- Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int J Pharm 1999; 184:1-6.
- Kydoneius AF. Fundamentals of transdermal drug delivery, CRC Press, Boca Raton Florida; 1987:3.
- Franz TJ, Tojo K, Shah KR, Kydonieus AF. Treatise on controlled drug delivery, Marcel Dekker, New York; 341-421.
- Vecchia BE, Bunge AL. Transdermal drug delivery, 2nd edition, Marcel Dekker, New York; 25-55.
- Shirley MN. Compatibility and synergy of permeation enhancers with solvents, excipients and drugs in Drug Permeation Enhancement, Hsieh DS, Ed., Marcel Dekker, New York 1994;91106.
- Barry BW. Editor Dermatological formulations, Percutaneous Absorption, Marcel Dekker, New York 1983; 127-233.
- Pongjanyakul T, Prakongpan S, Priprem A. Acrylic matrix type nicotine transdermal patches: in-vitro evaluation and batch-tobatch uniformity. Drug Dev Ind Pharm 2003; 29(8):843-53.
- Shin SC, Shin EY, Cho CW. Enhancing effects of fatty acid on piroxicam permeation through rat skins. Drug Dev Ind Pharm 2000; 26(5):563-6.
- Tipre DN, Vavia PR. Formulation, optimization and stability study of transdermal therapeutic system of nicorandil. Pharm Dev Technol 2002; 7(3):325-32.
- Verma PRP, Iyer SS. Controlled transdermal delivery of propranolol using HPMC matrices: Design and in-vitro and invivo evaluation. J Pharm Pharmacol 2000; 52:151-6.
- Adrian PF, Schiller R, Motzkers HW, Gunther C, Muller RH, Rolph L. Transdermal delivery of highly lipophilic drugs: in-vitro fluxes of antiestrogens, permeation enhancers and solvent from liquid formulations. Pharm Res 2002; 19(5):661-8.
- Cross SE, Roberts MS. Physical enhancement of transdermal drug application: Is delivery technology keeping up with pharmaceutical development. Curr Drug Deliv 2004; 1:81-92.
- Aqil M, Sultana Y, Ali A, Dubey K, Najmi AK, Pillai KK. Transdermal drug delivery systems of a beta-blocker-Design, invitro and in-vivo characterization. Drug Deliv 2004; 1(1):27-31.
- Vyas SP, Singh R, Asati RK. Liposomally encapsulated diclofenac for sonophoresis induced systemic delivery. J Microenapsul 1995; 12(2):149-154.
Abstract Views: 6
PDF Views: 1